Press Release
ZIOPHARM to Present at the G5: ThinkEquity Partners 5th Annual Growth Conference
NEW YORK, Sep 11, 2007 (BUSINESS WIRE) --
ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the G5: ThinkEquity Partners 5th Annual Growth Conference on Monday, September 17, 2007 at 9:00 a.m. PT (noon ET) at the St. Regis Hotel in San Francisco, CA. Dr. Lewis will provide an overview of the Company and an update on its clinical development programs.
The presentation will be webcast live and can be accessed by visiting the Investor Relations section at www.ziopharm.com. The webcast will be archived for ninety days.
About ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology, Inc. applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law.
ZIOP-G
SOURCE: ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology, Inc. Investors ZIOPHARM Investor Relations Suzanne McKenna, 646-214-0703 smckenna@ziopharm.com or Media Rx Communications Tina Posterli, 917-322-2565 tposterli@rxir.com
Copyright Business Wire 2007
News Provided by COMTEX
